After years of disappointing ALS clinical trial results, this year's Sheila Essey Award recipient for significant contributions in ALS research is shifting to prevention.
After disappointing phase 3 trial results in ALS, Amylyx will pull Relyvrio from the market but provide it free to patients who want to stay on the medication.
Treatments for amyotrophic lateral sclerosis and paroxysmal nocturnal hemoglobinuria have been given marketing authorization by the European Medicines Agency.
The FDA has rejected Clene Nanomedicine's application for accelerated approval for the experimental drug ALS drug, CNM-Au8, citing insufficient evidence.
Elon Musk s brain-chip startup Neuralink said on Tuesday it has received approval from an independent review board to begin recruitment for a human trial of its brain implant.